Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
Clinical trial NCT05056779 · WITHDRAWN
Trial details
- NCT number
- NCT05056779
- Sponsor
- Galderma R&D
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-01
- Primary completion
- 2023-07-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.